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Abstract
Background Chronic kidney disease (CKD) is a signiﬁ-
cant public health problem. Strategy for its early detection
is still controversial. This study aims to assess the cost-
effectiveness of population strategy, i.e. mass screening,
and Japan’s health checkup reform.
Methods Cost-effectiveness analysis was carried out to
compare test modalities in the context of reforming Japan’s
mandatory annual health checkup for adults. A decision
tree and Markov model with societal perspective were
constructed to compare dipstick test to check proteinuria
only, serum creatinine (Cr) assay only, or both.
Results Incremental cost-effectiveness ratios (ICERs) of
mass screening compared with do-nothing were calculated
as ¥1,139,399/QALY (US $12,660/QALY) for dipstick
test only, ¥8,122,492/QALY (US $90,250/QALY) for
serum Cr assay only and ¥8,235,431/QALY (US $91,505/
QALY) for both. ICERs associated with the reform were
calculated as ¥9,325,663/QALY (US $103,618/QALY) for
mandating serum Cr assay in addition to the currently used
mandatory dipstick test, and ¥9,001,414/QALY (US $100,
016/QALY) for mandating serum Cr assay and applying
dipstick test at discretion.
Conclusions Taking a threshold to judge cost-effective-
ness according to World Health Organization’s recom-
mendation, i.e. three times gross domestic product per
capita of ¥11.5 million/QALY (US $128 thousand/QALY),
a policy that mandates serum Cr assay is cost-effective. The
choice of continuing the current policy which mandates
dipstick test only is also cost-effective. Our results suggest
that a population strategy for CKD detection such as mass
screening using dipstick test and/or serum Cr assay can be
justiﬁed as an efﬁcient use of health care resources in a
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Introduction
A consensus has been established that chronic kidney
disease (CKD) is a worldwide public health problem [1, 2].
The effectiveness of its early detection and treatment to
prevent progression to end-stage renal disease (ESRD) and
premature death from cardiovascular disease has become
widely accepted [3], while the strategy of its screening is
still under debate [4]. Whereas high-risk strategies such as
routine screening for diabetes patients and as a part of
initial evaluation of hypertension patients are pursued in
Western countries [5, 6], some argue that population
strategies, such as mass screening, could be adopted in
Asian countries where CKD prevalence is high [7].
Japan has a long history of mass screening programme
for kidney diseases targeting school children and adults
since the 1970s. Both urinalysis and measurement of serum
creatinine (Cr) level have been mandated to detect glo-
merulonephritis in annual health checkup provided by
workplace and community for adults aged C40 years old
since 1992 [8]. However, glomerulonephritis was replaced
as the leading cause of ESRD by diabetic nephropathy in
1998, and the focus of mass screening policy for adults was
shifted to control of lifestyle-related diseases. In 2008, the
Japanese government launched a programme, Speciﬁc
Health Checkup (SHC) and Speciﬁc Counselling Guid-
ance, focusing on metabolic syndrome in order to control
lifestyle-related diseases, targeting all adults between the
ages of 40 and 74 years [9]. This is a combined programme
of mass screening followed by health education or referral
to physicians. During the process of this development of
SHC, different types of screening test for kidney diseases
were discussed in the health policy arena [10]. Abandon-
ment of dipstick test to check proteinuria was initially
proposed by the Ministry of Health, Labour and Welfare,
which was opposed by nephrologists who emphasised the
signiﬁcance of CKD. As a consequence, serum Cr assay
was alternatively dropped and dipstick test remained in the
list of mandatory test items [11]. However, those found
with proteinuria in SHC are not included in the health
education programme nor referred to physicians in the
following Speciﬁc Counselling Guidance that particularly
targets metabolic syndrome. At the time, much attention
was paid to a report from the USA which suggested the
cost-ineffectiveness of mass screening for proteinuria [12],
which encouraged the government to abandon dipstick test
in their initial proposal.
From the viewpoint of CKD control, the current SHC
and Speciﬁc Counselling Guidance are not adequate.
Therefore, to present evidence regarding CKD screening
test for the revision of SHC, which is due in 5 years from
its start in 2008, the Japanese Society of Nephrology set up
the Task Force for the Validation of Urine Examination as
a Universal Screening. Since cost-effectiveness analysis
provides crucial information for organising public health
programmes such as mass screening, the task force con-
ducted an economic evaluation as a part of their mission.
This paper presents the value for money of CKD screening
test demonstrated by the task force. The results have
implications for CKD screening programmes not only in
Japan but also for other populations with high prevalence
of CKD such as in Asian countries.
Methods
We conducted cost-effectiveness analysis of CKD screen-
ing test in SHC with a decision tree and Markov modelling
from societal perspective in Japan. In modelling, we car-
ried out a deliberate literature survey to ﬁnd the best
available evidence from Japan, while reports from overseas
were excluded. The PubMed database and Igaku Chuo
Zasshi (Japana Centra Revuo Medicina), a Japanese med-
ical literature database, were accessed with combinations
of relevant terms such as CKD, health checkup etc.
Additionally, we re-analysed our databases and carried out
surveys where applicable.
Participant cohort
We assume that uptake of SHC does not change regardless
of the choice of the test used for CKD screening, so we
model a cohort of participants in SHC. Since the sex and
age distribution of participants affects outcomes, we run
our economic model by sex and age strata. Probabilities of
falling into a sex and age stratum are adopted from a
nationwide complete count report of SHC in 2008 [13].
Each value is shown in Table 1, and we estimate outcomes
based on the prognosis of participants by initial renal
function. We also run our economic model for 25 initial
renal function strata deﬁned by the combination of ﬁve
levels of dipstick test results and ﬁve stages of CKD
according to estimated glomerular ﬁltration rate (eGFR)
derived from serum Cr level. Probabilities of falling into an
initial renal function stratum are calculated from the Japan
Tokutei-Kenshin CKD Cohort 2008, which is a large
cohort for the evaluation of SHC. Each value is shown in
Table 1.
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123Decision tree
Figure 1a shows our decision tree comparing a do-nothing
scenario with a screening scenario. After the decision node,
participants under the do-nothing scenario follow the
Markov model shown in Fig. 1b. For those under the
screening scenario, three types of screening test are con-
sidered: (a) dipstick test to check proteinuria only,
(b) serum Cr assay only and (c) dipstick test and serum Cr
assay. Other tests such as microalbuminuria and cystatin C
[14] are not considered, because they are not available
options in the context of this study.
Screened participants are portioned between CKD
patients who undergo treatment and those who are left
untreated through three chance nodes. The ﬁrst chance
node divides the participants between those who require
further examination and those left untreated. Participants
with (a) dipstick test only, C1?; with (b) serum Cr assay
only, Cstage 3; and with (c) dipstick test and serum Cr
assay, either C1? or Cstage 3, are screened as requiring
further examination. Those screened as requiring no further
examination follow the Markov model. These are imple-
mented by initial renal function stratum.
The second chance node divides participants screened as
requiring further examination into those who seek detailed
examination at health careproviders andthose whoavoid any
furtherexamination.Itsprobabilityisassumedat40.0%based
on the literature [15, 16] and of the opinion of an expert
committeesetupforthepurposeofthisstudy,whosemembers
areacknowledgedinthe‘‘Acknowledgements’’section.Those
who avoid further examination follow the Markov model.
The third chance node divides participants who under-
went further examination into those who undergo treatment
of CKD and those left untreated. We derived these prob-
abilities by initial renal function stratum with a Delphi
survey of the expert committee. Regarding the strata of
stage 3 CKD, a cut-off value of eGFR (50 ml/min/
1.73 m
2) and comorbidity such as hypertension, diabetes
and/or hyperlipidaemia are considered in order to depict
the difference in clinical practice when recommending start
of treatment [17]. We label early stage 3 CKD and
advanced stage 3 CKD according to this criterion. Among
stage 3 CKD patients, the probability of falling into
advanced stage 3 CKD by either eGFR \50 ml/min/
1.73 m
2 or having comorbidity is 83.5%, calculated from
the Japan Tokutei-Kenshin CKD Cohort 2008. Each value
is shown in Table 1. All participants follow the Markov
model after their completion of detailed examination.
Markov model
TheMarkovmodelconsistsofﬁvehealthstates:(1)screened
and/or examined, (2) ESRD, (3) heart attack, (4) stroke and
(5) death. Transitions between these states are indicated by
arrows. Although individuals follow various courses other
than these ﬁve health states and indicated transitions, we
model in this way based on available data and literature.
We set the span of staying in each state of the Markov
model at 1 year. Annual transition probabilities from (1)
screened and/orexamined to (2)ESRD with no treatment by
the initial renal function stratum are calculated from our
database of screened cohort in Okinawa Prefecture [18] for
this study, since there is no operational predictive model for
progression of CKD to ESRD such as Tangri et al. [19]i n
Japan. Each value is shown in Table 1. Reductions of these
transition probabilities brought about by treatment of CKD
(a) 
(b) 
Fig. 1 Economic model.
: Markov model
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123are set at42.1% based on Omae et al.[20], whoinvestigated
the effectiveness of angiotensin-converting enzyme inhibi-
tor in improving renal prognosis. This is a unique Japanese
evidence of treatment effectiveness evaluating progression
to ESRD which can be compared with our Okinawa cohort
[18]. The subsequent transition probabilities to (5) death are
calculated from the life expectancy of dialysis starters
according to a complete count report of Japanese patients on
dialysis [21]bysexandage.EachvalueisshowninTable 1.
Transition probabilities from (1) screened and/or
examined to (3) heart attack with no treatment are adopted
from an epidemiological study in Okinawa by Kimura
et al. [22] by initial dipstick test result, age and sex. Each
value is shown in Table 1. Reductions of these transition
probabilities brought about by treatment of CKD are set at
71.0% based on the Hisayama study by Arima et al. [23].
The subsequent transition probabilities to (5) death are
adopted from Kimura et al. [22] by age and sex for the ﬁrst
year, and from Fukiyama et al. [24] for the second year and
thereafter. Each value is shown in Table 1.
Transition probabilities from (1) screened and/or exam-
inedto(4)strokewithnotreatmentareadoptedfromKimura
et al. [22] by initial dipstick test result, age and sex. Each
value is shown in Table 1. Reductions of these transition
probabilities brought about by treatment of CKD are set at
69.3% based on Arima et al. [23]. The subsequent transition
probabilitiesto(5)deathareadoptedfromKimuraet al.[22]
by age and sex for the ﬁrst year, and calculated from the
Stroke Register in Akita of Suzuki [25, 26] for the second
year and thereafter. Each value is shown in Table 1.
A transition probability from (3) heart attack and (4)
stroke to (2) ESRD is adopted from an epidemiological
study in Okinawa by Iseki et al. [27].
Transition probabilities from (1) screened and/or exam-
ined to (5) death are adopted from Vital Statistics of Japan
2008 [28] by age and sex. Each value is shown in Table 1.
Wetake a life-longtime horizonso that the Markov cycle
is repeated until each age stratum reaches 100 years old.
Quality of life adjustment
In order to estimate outcomes, use of quality-adjusted life
years (QALYs) is recommended for economic evaluation
of health care [29, 30]. QALYs are calculated as the sum of
adjusted life-years experienced by a patient, where the
adjustment is made by multiplying time by weights linked
to the changing health state of the patient. The quality-
adjustment weight is a value between 1 (perfect health) and
0 (death), which is one of the health-related quality of life
measurements. Regarding (1) screened and/or examined,
weights are assigned according to CKD stage based on
initial renal function, using values adopted from Tajima
et al. [31]. Weights for (2) ESRD, (3) heart attack and (4)
stroke are cited from a past economic evaluation of anti-
hypertensive treatment in Japanese context by Saito et al.
[32].
Costing
From the societal perspective, costing should cover the
opportunity cost borne by various economic entities in
society. In the context of this study, costs borne by social
insurers and patients are considered, since the cost of SHC
is borne by social insurers and the cost of treatment is
shared by social insurers and patients in Japan’s health
system. The amount of direct payments to health care
providers by these entities is estimated as costs, while costs
of sector other than health and productivity losses are left
uncounted in this study. Cost items are identiﬁed along the
decision tree and Markov model: screening, detailed
examination, treatment of CKD, treatment of ESRD,
treatment of heart attack and treatment of stroke. Each
value is shown in Table 1.
Costs of screening were surveyed in ﬁve prefectures by
inquiring health checkup service providers’ price of adding
CKD screening test to a test package that does not include
renal function tests. Average price of those for (a) dipstick
test to check proteinuria only, (b) serum Cr assay only and
(c) dipstick test and serum Cr assay was ¥267 (US $3.0,
with US $1 = ¥90), ¥138 (US $1.5) and ¥342 (US $3.8)
per person, respectively. Cost of detailed examination is set
at ¥25,000 (US $278) per person according to the national
medical care fee schedule and a treatment model developed
by the expert committee. Annual costs of CKD treatment
per person are set at ¥120,000 (US $1,333) for stage 1
CKD, ¥147,000 (US $1,633) for stage 2 CKD, ¥337,000
(US $3,744) for stage 3 CKD, ¥793,000 (US $8,811) for
stage 4 CKD and ¥988,000 (US $10,978) for stage 5 CKD,
also from the national medical care fee schedule and a
treatment model developed by the expert committee.
Annual cost of ESRD treatment per person, ¥6,000,000
(US $66,667), is cited from a review of renal disease care
in Japan by Fukuhara et al. [33]. Annual cost of heart
attack treatment per person, ¥2,780,000 (US $30,889) for
the ﬁrst year and ¥179,000 (US $1,989) for subsequent
years, are cited from a past economic evaluation of car-
diovascular disease prevention in Japanese context by
Tsutani et al. [34]. Similarly, annual costs of stroke treat-
ment per person, ¥1,000,000 (US $11,111) for the ﬁrst year
and ¥179,000 (US $1,989) for subsequent years, are cited
from Tsutani et al. [34] as well.
Discounting
Both outcomes and costs are discounted at a rate of 3%
[30].
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To draw signiﬁcant policy implications from this economic
evaluation, policy options from status quo need to be
deﬁned. Under the current SHC, the dipstick test to check
proteinuria is mandatory, while serum Cr assay is not.
However, some health insurers voluntarily provide serum
Cr assay to participants in addition to SHC. We surveyed
health insurers in ﬁve prefectures and found that 65.4% of
them implement use of serum Cr assay. Also, we analysed
the Japan Tokutei-Kenshin CKD Cohort 2008 and found
that 57.3% of participants underwent use of serum Cr
assay. Therefore, we deﬁne the status quo regarding
screening test for CKD as 40% of insurers implementing
dipstick test only and 60% implementing dipstick test and
serum Cr assay.
Then we evaluate two policy options in this study:
‘Policy 1: Requiring serum Cr assay’, and ‘Policy 2:
Requiring serum Cr assay and abandoning dipstick test’.
Policy 1 means mandating use of serum Cr assay in addi-
tion to the currently used dipstick test, so that 100% of
insurers implement both dipstick test and serum Cr assay if
policy 1 is taken. Policy 2 is considered based on two
recent health policy contexts. One is the discussion aroused
during the development of SHC in which requiring serum
Cr assay only and abandoning dipstick test used in the
former occupational health checkup scheme attracted
substantial support. It is expected that such a policy option
will be proposed in the revision of SHC. Another relates to
the change in diagnosis criterion of diabetes [35], in which
a blood test to check the level of haemoglobin A1c instead
of a dipstick test to check urinary sugar level has become
pivotal. Implementing dipstick test for checking proteinuria
only bears scrutiny from the viewpoint of economic eval-
uation. We assume that 100% of insurers would stop
providing dipstick test if policy 2 is adopted.
We calculate incremental cost-effectiveness ratios
(ICERs) for these two policy options using our economic
model. ICER is a primary endpoint of cost-effectiveness
analysis, which is deﬁned as follows:
ICER ¼
Incremental cost
Incremental effectiveness
¼
CostNew policy   CostStatus quo
EffectivenessNew policy   EffectivenessStatus quo
This means the additional cost required to gain one more
QALY under new policy.
Sensitivity analysis
Economic modelling is fundamentally an accumulation of
assumptions adopted from diverse sources. Therefore, it is
imperative to appraise the stability of the model. We
perform one-way sensitivity analyses for our model
assumptions. Assumed probabilities about the participant
cohort, the decision tree and the Markov model are chan-
ged by ±50%. Reductions of transition probabilities
brought about by treatment are also changed by ±50%.
Utility weights for quality of life adjustments are changed
by ±20%. Costs are changed by ±50%. Discount rate is
changed from 0% to 5%. We also changed our assumption
about status quo that 40% of insurers implement dipstick
test only and 60% implement dipstick test and serum Cr
assay by ±50% as well.
Results
Model estimators
Table 2 presents the model estimators. Under the
do-nothing scenario, no patient is screened, with average
cost of renal disease care per person of ¥2,125,490
(US $23,617) during average survival of 16.11639 QALY.
When (a) dipstick test to check proteinuria only is applied,
832 patients out of 100,000 participants are screened, with
additional cost of ¥7,288 (US $81) per person compared
with the do-nothing scenario, for additional survival of
0.00639 QALY (2.332 quality-adjusted life days). When
(b) serum Cr assay only is applied, 3,448 patients are
screened with additional cost of ¥390,002 (US $4,333) per
person compared with the do-nothing scenario, for addi-
tional survival of 0.04801 QALY (17.523 quality-adjusted
life days). When (c) dipstick test and serum Cr assay are
applied, 3,898 patients are screened with additional cost of
¥395,655 (US $4,396) per person compared with the do-
nothing scenario, for additional survival of 0.04804 QALY
(17.535 quality-adjusted life days).
Model estimators of ICERs were calculated as
¥1,139,399/QALY(US $12,660/QALY)for(a)dipsticktest
only,¥8,122,492/QALY(US $90,250/QALY)for(b)serum
Cr assay only and ¥8,235,431/QALY (US $91,505/QALY)
for (c) dipstick test and serum Cr assay.
Cost-effectiveness
Table 3 presents the results of cost-effectiveness analysis.
Regarding the status quo that 40% of insurers implement
dipstick test only and 60% implement dipstick test and
serum Cr assay, 2,837 patients out of 100,000 participants
are screened, with average cost of screening and renal
disease care per person of ¥2,365,798 (US $212,922)
during average survival of 16.14777 QALY. Taking pol-
icy 1 that 40% of insurers currently using dipstick test only
start use of serum Cr assay screens more patients (3,898).
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123It costs more, but it gains more. Its incremental cost is
¥155,347 (US $1,726), and its incremental effectiveness is
0.01666 QALY (6.081 quality-adjusted life days), resulting
in ICER of ¥9,325,663/QALY (US $103,618/QALY).
Taking policy 2 that 40% of insurers currently using dip-
stick test only start use of serum Cr assay and abandon
dipstick test screens more patients (3,448) compared with
the status quo as well. It also costs more, but it gains more.
Its incremental cost is ¥149,694 (US $1,663), and its
incremental effectiveness is 0.01663 QALY (6.070 quality-
adjusted life days), resulting in ICER of ¥9,001,414/QALY
(US $100,016/QALY).
Stability of cost-effectiveness
One-way sensitivity analyses produce similar results not
only between policy 1 and policy 2 but also among three
model estimators of ICER. Therefore, we present a tornado
diagram of policy 1 as an example in Fig. 2. Ten variables
with large change of ICER are depicted. A threshold to
judge cost-effectiveness is also drawn, which is according
to World Health Organization’s (WHO) recommendation,
being three times gross domestic product (GDP) per capita
[36]. Its value is ¥11.5 million/QALY (US $128 thousand/
QALY) gain in 2009 in Japan.
The effectiveness of CKD treatment to delay progres-
sion to ESRD is found to be the most sensitive. Decreasing
the effect by 50% increases ICER to ¥16,280,537/QALY
(US $180,895/QALY). The effectiveness of CKD treat-
ment to prevent stroke is also found to be the 10th largest
change of ICER, but its range is limited.
The cost of treatment for stage 5 CKD is found to be the
second most sensitive. Increasing the cost by 50%
increases ICER to ¥14,404,335/QALY (US $160,048/
QALY). The cost of ESRD treatment is found to be the
ﬁfth largest change, and the change is in the opposite
direction; decreasing this increases ICER. Another cost
item depicted is the cost of treatment for stage 3 CKD,
which is found to be the sixth largest change.
The discount rate is found to be the third most sensitive.
Discounting at a rate of 5% makes ICER ¥11,373,185/
QALY (US $126,369/QALY). Since policy 1 can screen
CKD patients without proteinuria by use of serum Cr assay,
the prognosis of non-proteinuric stage 5 CKD without
treatment is found sensitive as the fourth and the seventh
largest change. The eighth largest change depicted relates
to the prevalence of CKD in participating population, i.e.
stage 2 CKD without proteinuria. The ninth largest change
is utility weight for ESRD.
Taking the threshold to judge cost-effectiveness, one-
way sensitivity analyses alter the interpretation of the
results for only three variables: reductions of transition
probabilities from (1) screened and/or examined to (2)
ESRD with the treatment of CKD; cost of treatment for
stage 5 CKD; and transition probability from (1) screened
and/or examined to (2) ESRD with no treatment by initial
renal function for stage 5 CKD without proteinuria.
Discussion
We conduct a cost-effectiveness analysis of CKD screening
test in SHC. Facing the scheduled revision of mandatory
test items, we appraise two possible policy options com-
pared with the status quo that 40% of insurers implement
dipstick test to check proteinuria only and 60% implement
Table 2 Model estimators
No. of patients
per 100,000
participants
Cost (¥) Incremental
cost (¥)
Effectiveness
(QALY)
Incremental
effectiveness
(QALY)
Incremental cost-
effectiveness ratio
(¥/QALY)
Do-nothing 0 2,125,490 16.11639
(a) Dipstick test only 832 2,132,778 7,288 16.12278 0.00639 1,139,399
(b) Serum Cr assay only 3,448 2,515,492 390,002 16.16440 0.04801 8,122,492
(c) Dipstick test and serum Cr assay 3,898 2,521,145 395,655 16.16443 0.04804 8,235,431
Table 3 Results of cost-effectiveness analysis
No. of patients
per 100,000
participants
Cost (¥) Incremental
cost (¥)
Effectiveness
(QALY)
Incremental
effectiveness
(QALY)
Incremental cost-
effectiveness ratio
(¥/QALY)
Status quo 2,837 2,365,798 16.14777
Policy 1: requiring serum Cr assay 3,898 2,521,145 155,347 16.16443 0.01666 9,325,663
Policy 2: requiring serum Cr assay
and abandoning dipstick test
3,448 2,515,492 149,694 16.16440 0.01663 9,001,414
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123dipstick test and serum Cr assay. Policy 1 is to mandate
serum Cr assay in addition to the current dipstick test, so
that 100% of insurers implement both dipstick test and
serum Cr assay. Policy 2 is to mandate serum Cr assay and
abandon dipstick test, so that 100% of insurers would stop
providing dipstick test and switch to serum Cr assay. Our
base-case analysis suggests that both policy options cost
more and gain more. Estimated ICERs are ¥9,325,663/
QALY (US $103,618/QALY) for policy 1 and ¥9,001,414/
QALY (US $100,016/QALY) for policy 2.
To interpret these ICERs, there is no established value of
socialwillingnesstopayforoneQALYgaininpublichealth
programmessuchasmassscreeninginJapan,althoughsome
suggest¥5 million/QALY(US $56 thousand/QALY)foran
innovative medical intervention [37]. We follow WHO
recommendation in this study, which is three times GDP per
capita [36]. Its value is ¥11.5 million/QALY (US $128
thousand/QALY) gain in 2009 in Japan. Given this thresh-
old, both policy 1 and policy 2 are judged as cost-effective.
Therefore, mandating serum Cr assay in SHC can be justi-
ﬁable as an efﬁcient allocation of ﬁnite resources for health.
Between policy 1 and policy 2, the ICER of policy 2 is
slightly more favourable than that of policy 1, while 450
more patients out of 100,000 participants are screened by
adopting policy 1. If secondary prevention of CKD is
emphasised as a policy objective in addition to efﬁciency,
policy 1 is an acceptable option as well as policy 2.
Our model estimators have a policy implication,
although estimated ICERs do not directly depict any mar-
ginal change in society. The ICER of (a) dipstick test only
compared with the do-nothing scenario, ¥1,139,399/QALY
(US $12,660/QALY), is remarkably favourable. This
implies that mass screening with dipstick test only is cost-
effective compared with abolishment of mass screening for
kidney diseases altogether. Therefore, continuing the cur-
rent policy, i.e. mandatory dipstick test, could be justiﬁable
as an efﬁcient resource allocation.
This contrasts with the reported cost-ineffectiveness of
annual mass screening for adults using dipstick test to
check proteinuria in the USA [12], although direct com-
parison cannot be made between the results of economic
evaluations under different health systems. The difference
could be attributable to the difference in the prevalence of
proteinuria among screened population, with 5.450% being
used in our model based on the Japan Tokutei-Kenshin
CKD Cohort 2008, while 0.19% is assumed in the US
study. Such epidemiological differences are known in
terms of not only quantity but also in quality [7]. The
prevalence of glomerulonephritis, especially IgA
nephropathy, is higher in Asian countries including Japan
compared with Western countries [10]. Also, the preva-
lence of renovascular disease such as ischaemic nephrop-
athy, with which patients are often non-proteinuric until
advanced stages of CKD, is lower in Asian countries [38].
The inclusion of heart attack and stroke into our model,
which are excluded in the US model [12], may have also
made the ICER more favourable.
There is a report of cost-ineffectiveness of population-
based screening for CKD with serum Cr assay from Canada
[39]. This Canadian model can be compared with our model
estimators of (b) serum Cr only compared with the
do-nothing scenario. Their health outcomes gain or incre-
mental effectiveness is 0.0044 QALY, which is smaller than
ours,0.04801QALY,whiletheirincremental costisC $463
(US $441, using US $1 = C $1.05), which is also smaller
than ours, ¥390,002 (US $4,333). These differences proba-
bly reﬂect the difference in the prevalence of CKD between
Canada and Japan. Regarding the efﬁciency of screening
programme, our model estimator of ICER, ¥8,122,492/
QALY (US $90,250/QALY), is slightly more favourable
than that of Canada, C $104,900/QALY (US $99,905/
QALY). However, the contradictory conclusion regarding
cost-effectiveness is not due to this difference but rather the
thresholdtaken.TheCanadianstudyadoptslowervaluesuch
Fig. 2 Tornado diagram of
policy 1. This tornado diagram
shows ten variables which are
found to be sensitive to the
change in assumptions. Ten
variables are presented, ordered
according to the size of the
change of ICER from top to
bottom. The change of ICERs is
represented by white bars when
increasing the variable or by
black bars when decreasing the
variable from base-case value.
The threshold to judge cost-
effectiveness is 3 9 GDP per
capita (¥11.5 million/QALY
gain)
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123as C $20,000 to C $50,000/QALY (US $19,048 to
US $47,619/QALY) following local practice [40].
Our sensitivity analysis suggests instability of the results
in only three variables, so our ﬁndings are robust to a
certain extent. The most sensitive variable is the effec-
tiveness of CKD treatment delaying progression to ESRD:
42.1% reduction is adopted in our economic model
according to the unique clinical evidence from Japan,
whose agent is angiotensin-converting enzyme inhibitor. It
is marginally larger than comparative values reported from
Western countries. Reductions in the rate of GFR decline
are 35.9% by Agodoa et al. [41], 39.8% by The GISEN
Group [42] and 22.5% by Ruggenenti et al. [43]. However,
we think our assumption of base-case value is reasonable in
two accounts: in light of the indication of angiotensin
receptor blockers [17], whose use is more tolerated than
angiotensin-converting enzyme inhibitors [44], and the
higher prevalence of glomerulonephritis including IgA
nephropathy, being a primary renal disease for ESRD, in
Japan [10], for which the effect of early treatment such as
renin–angiotensin system (RAS) inhibition, an immuno-
suppression, reduces risk of ESRD by 60% [45].
In regards to the other sensitive variables, we think the
prognosis of non-proteinuric stage 5 CKD without treat-
ment does not greatly undermine our ﬁndings of base-case
analysis, since the value is calculated from extended fol-
low-up of an established database [18]. Uncertainty of the
base-case value should be much less than the analysed
±50%. On the other hand, the cost of treatment for stage 5
CKD relates to one of the weaknesses of this study, as
discussed in the following.
There are weaknesses in this study. The most signiﬁcant
one is that our economic model depicts the prognosis of
CKD by initial renal function stratum. This approach is
taken because of the limitation of epidemiological data,
and it has little difﬁculty in estimating outcomes in terms
of survival. However, it becomes problematic when it
comes to costing. For example, a patient initially screened
as stage 1 CKD stays at (1) screened and/or examined
before transiting to the following health states such as (2)
ESRD. This means that a patient skips over stage 2 CKD to
5 CKD before progressing to ESRD. To estimate the cost
for this health state, the diversity of patients in terms of
progression of the CKD stages should be taken into
account. Our expert committee has developed treatment
models to understand this problem. This type of uncertainty
is larger in stage 1 CKD and smaller in stage 5 CKD, but
the cost of stages 1–4 CKD are not found to be so sensitive
in our sensitivity analysis. Also, we think that uncertainty
of the cost of stage 5 CKD, the second most sensitive
variable, is less than the analysed ±50%, and our ﬁndings
based on the base-case analysis are plausible. The problem
also affects quality of life adjustment, which tends to
produce larger QALY outcomes.
Other weaknesses include our assumption of 100%
adherence to treatment and so on. However, the most sig-
niﬁcant strength of this study is that our economic model
depends totally on evidence from Japan only, which could
justify our simpliﬁcation in modelling on data availability
basis. There is an opportunity for further reﬁnement of our
economic model, because a large-scale ﬁeld trial evaluat-
ing the effect of multifactorial treatment including lifestyle
modiﬁcation for early-stage CKD [46] is ongoing in Japan,
which will enable us to model progression of CKD with
more rigorous clinical evidence [47].
In conclusion, we, the Japanese Society of Nephrology
Task Force for the Validation of Urine Examination as a
Universal Screening, recommend to mandate use of serum
Cr assay in addition to the current dipstick test in the next
revision of SHC, from the viewpoint of value for money
and the importance of secondary prevention (Table 4). We
think that continuation of current policy, in which dipstick
test only is mandatory, is still a sensible policy option.
Development of adequate Speciﬁc Counselling Guidance
for screened participants is also recommended.
Whereas the primary objective of this study is to
appraise policy options in Japanese context, it also dem-
onstrates that good value for money can be expected from
mass screening with dipstick test to check proteinuria in
population with high prevalence; that is, a population
strategy could be adopted for control of CKD. However,
caution is needed when extrapolating this conclusion, since
the scope of costing of our economic model does not cover
the initial cost of launching mass screening. The model
here is based on currently running SHC. The practice of
annual mass screening for adults in Japan is quite excep-
tional, while such universal programmes are rarely found in
other countries [48].
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